KRAS and melanoma: In human melanomas, mutations of NRAS (10–15%) and KRAS (2%) are detectable, with NRAS having the substitution L61Q in about 80% of cases while G12V accounts for about 77% of the KRAS mutations according to a review by Cicenas et al. [18].